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Background: Colonic neuroendocrine neoplasms (NENs) are relatively rare tumors with an incidence rate of
0.11–0.21/100,000. NENs account for approximately 0.4% of colorectal neoplasms. Cutaneous metastases of colonic
neuroendocrine carcinomas (NECs) are very infrequent, while cases of scalp metastasis are even fewer. Cutaneous
metastases are more rare than visceral metastases and usually develop later; therefore, cutaneous metastases as
initial distant metastases can be easily overlooked. This is the second case report of a colonic NEC with scalp
metastasis. Compared with the previous case, in this instance scalp metastasis developed before visceral metastasis,
and the cutaneous lesions were confined to the scalp alone.
Case presentation: A 62-year-old Chinese man, who had undergone radical surgery for a “locoregional” colonic
NEC one and half months before, came to our hospital for adjuvant chemotherapy. We found multiple scalp
nodules during physical examination. Moreover, these nodules had occurred and had not been detected prior to
the patient undergoing radical surgery. The scalp nodules proved to be metastases from colonic NEC as determined
using pathological and immunohistochemical examinations following lumpectomy. After one and half months,
visceral metastases were detected in this patient. Ultimately, the patient died two months later.
Conclusions: In this report an unusual case of a colonic NEC with initial distant metastasis confined to the scalp is
presented. This case is unusual because of the development of cutaneous metastasis before visceral metastasis. The
scalp metastasis were initially overlooked, leading to inaccurate staging and radical surgery that was not curative.
This demonstrates that distant metastasis can occur during the early phase of tumor growth in these aggressive
lesions. Thus, the possibility of distant metastases should be assessed in the initial work up to avoid mistaken
clinical staging especially when distant metastases occur only in skin.
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Neuroendocrine neoplasms (NENs) are rare tumors ori-
ginating from neuroendocrine cells and include a series
of heterogeneous tumors. Their presentation can be in-
dolent, low-grade malignant or high-grade malignant.
These tumors can synthesize, store and secrete peptide
hormones. Excessive hormones can cause corresponding
clinical symptoms. According to the degree of differenti-
ation, NENs have been divided into well differentiated
NENs and poorly differentiated NENs in the 2010 World* Correspondence: 29091740@qq.com
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gestive system, with the former being termed a neuroen-
docrine tumor (NET), and the latter, a neuroendocrine
carcinoma (NEC) [1]. Cases of colonic NECs are very
unusual and data from the Norwegian Registry of Can-
cer from 1993–2004 showed that the incidence rate of
colonic NENs was 0.25/100,000 and 31.5% of colonic
NENs were classified as NECs [2]. Distant metastasis of
NECs mostly occurred in the viscera, while cases of scalp
metastasis were rarely reported. A literature review in
PubMed revealed only four case reports [3-6], however,
primary colonic NEC was present in only one case [6];
these cases are summarized in Table 1.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Table 1 Cases of scalp metastases of NEC reported in the literature




[3] F/31 Uterine cervix Bone, lung, pleura, spinal cord, lymph nodes No 2
[4] F/33 Uterine Cutaneous metastases of chest, back, abdomen, axilla
and neck
Yes >1
[5] M/20 Bladder Lung, retroperitoneal lymph nodes, skin of other sites No 1
[6] M/42 Colon Liver, sphenoid, cavernous sinuses, bone, cutaneous
metastasis of shoulder
No 1
Our case M/62 Colon Liver, pancreas, lymph nodes Yes >3
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multiple scalp metastases. Furthermore, this case has
three features: (1) cutaneous metastases developed only
in the scalp with no cutaneous metastases found at other
sites; (2) there were multiple scalp metastases (>3); and
(3) scalp metastases developed before visceral metasta-
ses. This case report, therefore, will focus attention on
scalp metastases of an NEC. We have also reviewed the
literature concerning gastroenteropancreatic neuroendo-
crine carcinomas (GEP-NECs) in this article.
Case presentation
The patient was a 62-year-old man who was admitted to
a local hospital because of abdominal pain and ab-
dominal distension. Colonoscopy revealed a colon mass
and a computed tomography (CT) scan of the abdomen
showed that the mass infiltrated the serosa of the trans-
verse colon, which was adjacent to the omentum majus
with mesenteric lymph node metastases. The patient
then went to a cancer hospital where a CT scan of his
thorax and abdomen showed no distant metastases. Rad-
ical surgery was performed to remove his colon cancer
on Feb 16th, 2013. Because the primary tumor was re-
moved in a different hospital, we were unable to acquire
a specimen of the resected primary tumor, however, we
were able to obtain the pathological examination report.
According to the report, the primary tumor was a poorly
differentiated NEC of the right colon (grade 3) with a
mass size of 9 × 5 × 3.5 cm. The tumor infiltrated the
full thickness of the intestinal wall and extended into
the extraserosal fibrous and adipose tissue, and 5/19 ex-
cised lymph nodes were positive for metastases. There
were vessel cancer emboli, neural invasion, four cancerFigure 1 Multiple reddish nodules in the subcutis of the scalp.nodules around the tumor, four cancer nodules on the
mesenterium and five cancer nodules on the omentum
majus. The immunohistochemical report showed that
tumor cells were stained positive for cytokeratin AE1/3,
cytokeratin CAM5.2, chromogranin A (CgA), synaptophy-
sin (Syn), CD56 antigen, CDX-2 and Ki-67 (approximately
30-50%).
The patient came to our hospital for adjuvant che-
motherapy on March 28th, 2013. Multiple nodules in
the scalp were found using physical examination (>3)
(Figure 1) and no cutaneous nodules were palpated at
other sites. The patient recalled that he had some red-
dish papules on his scalp before surgery, but he did not
mention them to the surgeon. These papules became
gradually larger and formed multiple nodules. Labora-
tory tests done on admission showed that carbohydrate
antigen 19-9 was 51.27 U/mL (normal, <37 U/mL), carbo-
hydrate antigen 125 was 95.09 U/mL (normal, <35 U/mL)
and neuron-specific enolase (NSE) was 123.9 μg/L (nor-
mal, <17 μg/L). Magnetic resonance of the head showed
multiple space-occupying lesions with a rich blood supply
in the soft tissue of his scalp (Figure 2). Our patient re-
ceived one cycle of systemic chemotherapy with a regimen
of etoposide 100 mg/m2 IV on days 1-3 and cisplatin
25 mg/m2 IV on days 1-3.
He underwent a lumpectomy and transfer of a skin
flap after chemotherapy. The largest nodule was about
2.5 cm in diameter, and it was removed during surgery.
Pathological examination of the scalp nodule showed
that the size of tumor was 2 × 2 × 1 cm. Hematoxylin-
eosin staining showed that the scalp metastasis was
composed of small to medium-sized cells with mini-
mal cytoplasm, irregularly shaped nuclei with granular
Figure 2 Head MRI showed multiple lesions in the soft tissue of the scalp.
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cells were arranged in diffuse and nesting patterns and mi-
toses were numerous (24 mitoses per 10 high power
fields) (Figure 3). Immunohistochemical analyses showed
that tumor cells stained positive for CD56 (weak), Syn
(diffuse), CDX-2 (strong), pan-cytokeratin, cytokeratin 8,
cytokeratin CAM5.2 and Ki-67, with the Ki-67 index
reaching up to 60% (Figure 4). On the other hand, tumor
cells stained negative for CK20, transcription termination
factor 1 (TTF-1), melanoma antibody (HMB45) and CgA
(Figure 5). On the basis of the pathological examination
and medical history, the metastatic tumor of the scalp was
considered to be a poorly differentiated carcinoma that
originated from the colon with necrosis and neuroendo-
crine differentiation (NEC grade 3).
But other scalp nodules became larger and new nod-
ules appeared after surgery. The patient received one
additional cycle of the same chemotherapy regimen after
April 23rd, 2013. Tumor progression was considered to
have occurred once scalp nodules further increased in
size and NSE levels further rose after chemotherapy. A
CT scan of the patient’s abdomen was performed on
May 14th, 2013. The scan showed that he had liver, pan-
creatic and lymph node metastases. Once visceral metas-
tases were found, the patient received subcutaneous
injection of octreotide acetate 0.1 mg per 8 hours for
three days as of May 26th, 2013, and intramuscular in-
jection of 20 mg octreotide acetate microspheres everyFigure 3 Microscopic features of scalp nodule. (A) Tumor cells arranged
staining, ×50). (B) Irregular and small to medium-sized tumor cells with sca
cells (hematoxylin-eosin staining, ×400).28 days three days later. Finally the patient received pal-
liative and supportive treatment, and died of disease pro-
gression one month later.
Conclusions
The gastrointestinal tract constitutes the most common
site of origin of extra-pulmonary NECs, which can ori-
ginate anywhere in the gastrointestinal tract [7]. The in-
cidence rate of GEP-NENs is about 2–5/100,000 [8,9].
Functional NET is often accompanied by corresponding
neuroendocrine symptoms. On the contrary, NECs are
usually non-functional and without neuroendocrine symp-
toms. As a result, early-stage patients with NECs often
have no specific signs or symptoms making early diagnosis
very difficult, such that a majority of these patients already
have disseminated disease at diagnosis [10-12]. The an-
nual incidence of colonic NENs is 0.11–0.21/100,000 and
NENs make up 0.4% of colorectal neoplasms [1]. Con-
sequently when a mass is discovered in the colon, we
seldom consider a diagnosis of a colonic NEC; rather a
diagnosis of a colon adenocarcinoma is considered first.
NSE has been shown to have a high diagnostic value in
NECs [13,14]. The likelihood of an NEC is high when a
patient has a colon mass that is accompanied by elevated
serum NSE. At the time of initial diagnosis, extensive me-
tastases usually do not appear in colonic adenocarcinoma,
but distant metastasis often developed in NECs because of
its invasive nature.in diffuse and nesting patterns in the subcutis (hematoxylin-eosin
nty cytoplasm, hyperchromatic nuclei and distinct nucleoli in some
Figure 4 Immunohistochemical analyses of tumor cells. (A) Strongly positive staining of Syn (×200). (B) Strongly positive staining of CDX2
(×200). (C) Ki-67-positive nuclei (×200). (D) Weakly positive staining of CD56 (×200).
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this patient was considered to have regional disease and
underwent radical surgery with curative intent. If scalp
metastases had been found before surgery, a palliative
operation may have been more suitable for this patient.
Because of the high incidence of distant metastasis in
NECs, when the patient was diagnosed with an NEC, a
comprehensive preoperative physical examination and
staging evaluation were necessary. When morphological
imaging fails to find distant metastasis and distant metas-
tasis is highly suspected, a positron-emission tomography-
CT (PET-CT) examination should be done to acquireFigure 5 Immunohistochemical analysis showed that tumor
cells were negative for CgA (×200).accurate clinical staging. Since cutaneous metastasis are
infrequent in NECs and often overlooked, scalp metasta-
ses were not found prior to surgery that resulted in wrong
preoperative staging in this case. From the medical history
of this patient, scalp metastases occurred earlier than vis-
ceral metastases. So when the initial diagnosis of a GEP-
NEC was made, we should have paid attention to whether
scalp or cutaneous metastases were present.
In terms of the pathological diagnosis of NENs, grad-
ing of NENs is done according to the degree of prolifera-
tive activity of tumor cells, which is measured using two
criteria, mitotic figures and (or) Ki-67 index. NENs of
grade 1 or 2 are NETs, and NENs of grade 3 are NECs.
Tumor cells of NETs are arranged in a characteristic
organoid shape with nesting, and trabecular or gyriform
patterns [15]. The cells are relatively uniform with round
to oval nuclei having indistinct nucleoli and a coarsely
granular chromatin pattern [1], expressing general mar-
kers of neuroendocrine differentiation (usually diffuse
and intense CgA and Syn) [1]. In contrast, NECs have a
more sheetlike or diffuse architecture with irregular nuclei
and less cytoplasmic granularity [15]. Immunoexpression
of neuroendocrine markers is more limited (diffuse ex-
pression of Syn, faint or focal staining for CgA) [1].
Representative NECs include small cell NECs (small cell
carcinoma for short) and large cell NECs, while mor-
phology resembles that of the corresponding lung tumor.
Tumor cells of small cell carcinoma are small, round or
oval like lymphocytes and some cells are elongated like fu-
siform; moreover cytoplasm is minimal. In this kind of
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the nucleoli are inconspicuous and mitoses are numerous.
Small cell carcinoma takes on a diffuse distribution or nes-
ting arrangement, often accompanied by necrosis. Cells of
small cell carcinoma are generally less than three times
the size of lymphocytes. However, cells of large cell NECs
are generally larger than three times the size of lympho-
cytes with coarse granular chromatin, prominent nucleoli
and abundant cytoplasm. In large cell NECs, necrosis and
mitoses are common, and the tumor takes on organoid,
nesting, trabecular, rosette-like or palisading pattern.
Hematoxylin-eosin staining showed that in this case
the scalp metastasis consisted of small to medium-sized
tumor cells arranged in nesting patterns, which were
in line with the features of an NEC. Further immuno-
histochemical analyses showed that tumor cells stained
positive for Syn and CD56, which are neuroendocrine
markers, while no staining for CgA indicated that the
tumor was poorly differentiated. Nuclear staining of
Ki-67 was positive and the Ki-67 index reached 60%,
which was in accord with a grade 3 NEC. Cutaneous
metastasis of NECs should be differentiated from Merkel
cell carcinoma (MCC) and its origin should be investi-
gated. CK20 is commonly positive in MCC, but it is usu-
ally negative in NECs at other sites [16]. CDX2 and
TTF-1 are highly specific markers of gastrointestinal
tract NENs and pulmonary NENs, respectively [17,18].
Tumor cells of scalp nodules were positive for CDX2,
but negative for TTF-1 and CK20 in this case; therefore,
scalp nodules were not MCC and originated from the
colon.
Cases of GEP-NECs are rare and just a few large-scale
clinical studies have been conducted. Because the clin-
ical behavior of GEP-NECs is similar to that of small cell
lung cancer (SCLC), treatment modalities are usually
based on those prescribed for SCLC; therefore, adjuvant
treatment with chemotherapy and/or radiotherapy should
be given even after a definitive complete surgical resection
[7]. The recommended regimen of adjuvant chemotherapy
involves the combination of etoposide and cisplatin/carbo-
platin [19], and usually 4–6 cycles are administered [7].
Carboplatin and irinotecan seemed to be at least equally
effective compared with cisplatin and etoposide [7,20,21].
Indeed, irinotecan was even better than etoposide in a
multicenter retrospective analysis [22]. Second-line the-
rapy for NECs is based on that used to treat relapsed
SCLC, such as irinotecan, topotecan, paclitaxel, docetaxel,
vinorelbine and gemcitabine [7]. In addition, a retrospec-
tive study showed that temozolomide, either alone or in
combination with capecitabine or bevacizumab, attained a
response rate of 33% as second-line therapy in patients
with mostly GEP-NECs, but capecitabine or bevacizumab
did not seem to have any additional effect compared to
temozolomide [23]. Although the mammalian target ofrapamycin signaling pathway inhibitor everolimus elicits a
good response in patients with well differentiated NET,
those with NECs are usually excluded from clinical trials
(RADIANT 2, RADIANT3) because of their aggressive
nature [24,25]. Thus, whether patients with NECs will re-
spond to everolimus still needs to be confirmed. Somato-
statin analogues (SSA) helped to control the syndrome
and reduce circulating markers in GEP-NENs [26,27], but
their antiproliferative effect was much less clear and dis-
ease stabilization was more common [28-30]. The com-
bination of SSA and chemotherapy can be synergistic in
the treatment of NETs [31], however, SSA with chemo-
therapy to treat NECs has only been evaluated in a phase
II study [32]. Currently there is no evidence regarding the
efficacy of the combination of SSA and chemotherapy in
the treatment of GEP-NECs. Similarly, the vascular endo-
thelial growth factor receptor-tyrosine kinase inhibitor su-
nitinib has not been evaluated in the treatment of NECs
[33]. Our patient received etoposide and cisplatin as first-
line chemotherapy, but did not respond. Since the patient
had an NEC, SSA did not have any therapeutic effect.
Prognostic factors were also analyzed in NECs. Several
studies have illustrated that the extent of the disease, pa-
tient performance status, Ki-67 index, maximal standard
uptake value of a PET-CT examination and primary site
were the best predictors of survival or response, how-
ever, patients with primary colonic NECs seemed to have
shorter survival [8,11,12,34-36]. Blood levels of platelets
and lactate dehydrogenase were strong predictors of sur-
vival as well [12]. The tumor of this patient, derived from
the colon, was extensive with a high Ki-67 index, indi-
cative of a poor prognosis. Postoperative survival of this
patient was only five months. Primary drug resistance to
chemotherapy occurred in this patient and receiving oc-
treotide microspheres did not cause tumor remission. In
conclusion, NECs are extremely high-grade malignancies,
and therapeutic efficacy and prognosis are poor in patients
with these performances.Consent
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